AAV transduction of dopamine neurons with constitutively active rheb protects from neurodegeneration and mediates axon regrowth

Kim, Sang Ryong, Kareva, Tatyana, Yarygina, Olga, Kholodilov, Nikolai, Burke, Robert E·2012·Molecular Therapy
DOI 10.1038/mt.2011.213

Cited by (107)

Items 101–107 of 107

  1. mGluR5 Modulation as a Treatment for Parkinson’s Disease
    Kyle Farmer · 2018
  2. The Role of Brain Derived Neurotrophic Factor (BDNF) in Regulating α-synuclein Pathology in Primary Microglia and Neurons.
    Carley Paquette · 2023
  3. Inhibition of granule cell dispersion and seizure development by AAV1-AEG-1 administration in a mouse model of TLE
    Sang Ryong Kim, Eunju Leem, Sehwan Kim, Chanchal Sharma, Youngpyo Nam, Tae Yeon Kim, Minsang Shin, Seok‐Geun Lee, Jaekwang Kim · 2023 · Research Square
  4. Novel therapeutics for diverse neurodegenerative disorders
    Rameshwar Nath Chaurasia, T.T. Favas · 2024 · Elsevier eBooks
  5. Étude de la propagation de l'alpha-synucléine de l'hôte vers le greffon dans la maladie de Parkinson
    Maëlig Patrigeon · 2022 · theses.fr (ABES)
  6. AAV Vector‐Mediated Modulation of Signaling Pathways in Neurological Disorders: Insights From Cellular, Animal, and Human Studies
    Majid Reza Farrokhi, Kamran Hosseini · 2026 · Cell Biochemistry and Function
  7. ATF4 activates a transcriptional program that chronically suppresses mTOR activity and promotes neurodegeneration in Parkinson disease models
    Matthew D. Demmings, Erica A. Kane, Elizabeth C. Tennyson, Kate Hurley, Joy Zhao, Nicholas A. Cruickshanks, Victoria Ciz, Jordan M Krupa, Stephen Pasternak, Sean P. Cregan · 2026 · Cell Reports